Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  5.00 4.24% 123.00 1,202,697 16:35:10
Bid Price Offer Price High Price Low Price Open Price
122.50 123.50 124.00 114.50 120.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -29.43 -36.75 162
Last Trade Time Trade Type Trade Size Trade Price Currency
17:18:48 O 25,378 123.00 GBX

4d Pharma (DDDD) Latest News

More 4d Pharma News
4d Pharma Investors    4d Pharma Takeover Rumours

4d Pharma (DDDD) Discussions and Chat

4d Pharma Forums and Chat

Date Time Title Posts
20/1/202123:464D Pharma 2018 - from Ј2 back up to Ј10+16,856
03/12/202022:094d Pharma581
17/11/202020:53DDDD : 4D and the Microbiome sector-
09/11/202007:424D Pharma - Best Risk Reward Play on AIM12
08/3/202021:164D Pharma (DDDD) One to Watch 8

Add a New Thread

4d Pharma (DDDD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-20 17:25:12123.0025,37831,214.94O
2021-01-20 16:35:10123.009,01611,089.68UT
2021-01-20 16:29:59122.50363444.68AT
2021-01-20 16:29:59122.50292357.70AT
2021-01-20 16:29:57123.50370456.95AT
View all 4d Pharma trades in real-time

4d Pharma (DDDD) Top Chat Posts

4d Pharma Daily Update: 4d Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DDDD. The last closing price for 4d Pharma was 118p.
4d Pharma Plc has a 4 week average price of 107p and a 12 week average price of 87.80p.
The 1 year high share price is 183p while the 1 year low share price is currently 23.50p.
There are currently 131,392,242 shares in issue and the average daily traded volume is 1,795,713 shares. The market capitalisation of 4d Pharma Plc is £161,612,457.66.
the stigologist: Evelo January 2021 Corporate Presentation Note how they foreground the SUCCESSFUL trial but hardly mention the unsuccessful trial with Merck Keytruda they had to pull Slow kids at the back might want to see how successful NASDAQ CEOs with rising share prices act (yes that includes you Duncan if you still haven't got the message) Also some nice explanations of the centrality of the gut to tackling diseases around the human body htTps://
swallowsflysouth: magli, i have been taking gut bacteria for quite a while as per my previous posts. swallowsflysouth - 15 Oct 2020 - 18:53:44 - 11769 of 16568 4D Pharma 2018 - from Ј2 back up to Ј10+ - DDDD While researching DDDD i came across Bifidobacterium breve (B. breve)which is a highly beneficial bacteria, in fact, it’s one of the most helpful strains out there. Now this is being used by DDDD - "Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration" . This information comes from the document below. The point being this bacteria is available in a gut bacteria supplement called probio7 which is believed to give some protection again flu. I assume that they are using a slightly different strain from that being trialed by DDDD for use again cv-19 lung inflammation. However, it may as it is related give some protection against cv-19 ? Just a random thought, I am taking it as it is helping with my insomnia It has also give me more energy. hxxps:// swallowsflysouth - 15 Oct 2020 - 19:49:12 - 11779 of 16568 4D Pharma 2018 - from Ј2 back up to Ј10+ - DDDD Devonlad, they must have a different strain, and i'm positive a superior strain. They wouldn't have been able to get the patent if it had been the same strain. The Holland and Barrett version also fixed my Diverticulitis. The probios on offer are a stab in the dark, totally different from what DDDD are doing. Once DDDD and other gut bacteria companies get going in a serious way, pinpointing the different diseases then probio companies will be history. However, at this moment in time they are the best that are on offer be it of a somewhat hit and miss nature.
devonlad: MickinVest - I was thinking exactly the same thing. No more notifications though and I expect he will be clearing down the lot now. Definitely a lot os stock around and he is probably the only source with that much. All fairly irrelevant, we have been here before at 40p, 90p and now, the nasdaq listing and associated news flow will take care of that. A lot of buying interest this afternoon supporting the share price now at this price, the trading chart is very close to giving a buy signal so I expect a stronger week but I have more than enough now.
billthebank: The Americans do get very excited you cant deny it.The volatility yesterday was pretty electric so in answer who knows!! But it wouldnt surprise me to see DDDD pushing a lot higher and soon!!! It really is way undervalued with what is going in here. I am expecting this to be way beyond our present share price within the next three months poss even end of Jan or how about a wee ramp todayyyy!
frrinvest: 2350220 I don't think there will be any news until nearer Nasdaq. But that's not to say they won't push the price up in the meantime, especially as traders have sold out until the new year. When they come back they will have to buy at higher price. Just my thoughts but I do see share price rising fairly rapidly in the near term.
nash81: made profit from EQT and now looking where is to park my money. decided to buy into IIP yesterday - assets in india with NAV at 15p. share price now only 1p, could give me 10bags also now looking at DDDD - what is the target in here?
aimbagger: LOAC's share price is equivalent to c114p I believe so buying DDDD is more attractive currently.
someuwin: No shorts showing now. (< 0.5% don't register) so looks like whatever reason they had for trying to hold the share price back is now over. Note that the chart will show short positions going back to 2012. There was no short positions even as DDDD fell from £10 to £1. They only felt the need to short in the last few months! Hopefully the start of the big rise to NASDAQ.
hms_trader: 4Ds US appointed broker will, to capitalise on the Arbitrage opportunity and if there is a mismatch in price between the UK and US listing to create equality in the price, buy AIM shares and sell on the NASDAQ. This will ensure share prices remain broadly similar on the two exchanges. This is spelt out in the two recent lengthy RNS'
captain james t kirk: wayneg My understanding is that through your OTC purchase you have bought 4D shares trading on the AIM in London. The "Consideration shares" to be issued as part of the merger with LOAC will be converted into 4D ADS's at a ratio of 8 consideration shares for every 4D ADS and traded on the Nasdaq. In effect this will be a different market to the ordinary shares traded in London but there will be some form of share price equalisation between the two markets in a similar way that stocks presently listed on two seperate exchanges broadly level up or down. In theory, if 4D is trading at £1 on the AIM (exchange rate £1 = $1.30) then a 4D ADS will be around $10.40. You are correct that the ticker for the Nasdaq listing is LBPS and DDDD will remain the ticker on the AIM. Have you investigated any brokers that allow you to deal directly on the AIM ? It's not a recommendation but eToro springs to mind. Good luck.
4d Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 03:26:56